StockNews.AI
HURA
StockNews.AI
77 days

TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

1. TuHURA raised $12.5 million in a private offering and $3 million via warrant exercise. 2. Funding will support Phase 3 trial of IFx-2.0 and Phase 2 trial for AML.

3m saved
Insight
Article

FAQ

Why Bullish?

The substantial capital raised positions TuHURA favorably for key trials, potentially boosting investor confidence. Historical examples show that funding for clinical trials often leads to positive market reactions if trial results are promising.

How important is it?

The capital raised is crucial for TuHURA's growth initiatives, indicating strategic progress that could enhance shareholder value.

Why Long Term?

The funding allows TuHURA to advance critical trials that could yield significant developments over the next few years, similar to how advancements in clinical trials can positively influence biotech stocks over time.

Related Companies

KNTMRNAGENE
Secures $12.5 million of commitments in a private offering Secures an additional $3.0 million through payment of cash exercise price of warrants Funding provides capital for: Initiation of planned Phase 3 accelerated approval trial of IFx-2.0 targeting 40% enrollment by 2-2025 year end Acquisition of and initiating a Phase 2 trial in NPM1 mutated AML, a novel VISTA inhibiting antibody through closing of Kineta merger Advancing first-in-class immune modulating bi-specific, and bi-functional Antibody Drug Conjugates (ADC) and Antibody Peptide Conjugates (APCs) TAMPA, Fla. , June 3, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that it has entered into a definitive securities purchase agreement for the issuance and sale in a private placement of an aggregate of $12.5 million of shares of its common stock, for an aggregate of 4.6 million shares, together with warrants to purchase an equal number shares of common stock at an exercise price of $3.3125 per warrant share.

Related News